Fusion Antibodies’ (FAB.L) year-end trading update confirms unaudited FY26 revenues of £2.13m and a significant improvement in gross margin, with year-end cash of £1.04m, broadly in line with Allenby forecasts. Unaudited FY26 revenues, although up by 9%, were flattered by the recent sale of IP to Finn Therapeutics, which generated a one-off contribution of £250k that also helped boost gross margin. Adjusting for this, underlying sales were £1.9m, slightly down on FY25 (although FY26 H2 sales wer ....
